-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Insmed, Lowers Price Target to $201

Benzinga·11/02/2026 14:13:08
语音播报
Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $205 to $201.